PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021
                Monthly information related to total number of voting rights and shares composing the share capital – May 3 1 , 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
View HTML
Toggle Summary ERYTECH to Participate in Upcoming Virtual Investor Conferences in June
ERYTECH to Participate in Upcoming Virtual Investor Conferences in June Lyon (France) and Cambridge, MA (U.S.), May 2 6 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary Erytech’s Combined Shareholders’ Meeting on June 25, 2021
         ERYTECH’S COMBINED SHAREHOLDERS’ MEE TING ON JUNE 25, 2021 Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting SS RELEASE          Lyon (France), May 25 , 2020 – Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2021
                 Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 20 2 1 Conference call and webcast on Wednesday, May 5, 2021 at 8:30am EST/ 2:30pm CET          TRY b eCA-1, Phase 3 clinical trial in 2 n d line pancreatic cancer, fully enrolled, and on track for final results
View HTML
Toggle Summary ERYTECH Announces $30.0 Million Registered Direct Offering
ERYTECH Announces $ 30.0 Million Registered Direct Offering Lyon (France) and Cambridge, MA (U.S.), April 2 9 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext:   ERYP) (the “Company”) , a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Reports Cash Balance at End of Q1 2021 and Announces the Details of its 2021 Q1 conference call
ERYTECH Reports Cash Balance at End of Q1 202 1 and Announces the Details of its 2021 Q1 conference call Publication of Q1 2021 results on 4 May 2021 after market close Lyon (France) and Cambridge, MA (U.S.), April 2 9 , 202 1 – ERYTECH Pharma (Nasdaq & Euronext:   ERYP), a clinical-stage
View HTML
Toggle Summary ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting F irst step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the
View HTML
Toggle Summary ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Announces Completion of First Cohort i n a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer No d ose -l imiting t oxicity reported in the first dose cohor t Encouraging clinical activity observed in first patients Trial will be escalated to the next dose
View HTML
Toggle Summary ERYTECH to Participate in Upcoming Virtual Investor Conferences in April
ERYTECH to Participate in Upcoming Virtual Investor Conferences in April Lyon (France) and Cambridge, MA (U.S.), April 7, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Top